|
US4110368A
(en)
|
1972-07-24 |
1978-08-29 |
American Cyanamid Company |
Hydro substituted prostanoic acids and esters
|
|
US4346110A
(en)
|
1981-06-01 |
1982-08-24 |
Merrell Toraude Et Compagnie |
Method for treating depression
|
|
JPS61149964A
(ja)
|
1984-12-25 |
1986-07-08 |
Canon Inc |
電子写真感光体
|
|
US4670196A
(en)
|
1985-09-05 |
1987-06-02 |
Norton Company |
Tower packing element
|
|
DE3765646D1
(de)
|
1986-01-24 |
1990-11-29 |
Toray Industries |
2,5,6,7-tetranor-4,8-inter-m-phenylen-pgi2-derivate.
|
|
GB8827885D0
(en)
|
1988-11-30 |
1989-01-05 |
Wellcome Found |
Novel heterocyclic pesticidal compounds
|
|
US5639600A
(en)
|
1994-08-05 |
1997-06-17 |
The Regents Of The University Of California |
Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
|
|
DE19623142A1
(de)
|
1996-06-10 |
1997-12-11 |
Huels Chemische Werke Ag |
Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung
|
|
BR9713182A
(pt)
|
1996-08-28 |
1999-11-03 |
Procter & Gamble |
Amidas de ácido fosfìnico como inibidores de metalo protease de matriz
|
|
US7087648B1
(en)
|
1997-10-27 |
2006-08-08 |
The Regents Of The University Of California |
Methods for modulating macrophage proliferation using polyamine analogs
|
|
US6458781B1
(en)
|
1998-04-27 |
2002-10-01 |
David Thomas Connor |
Substituted diarylalkyl amides as calcium channel antagonists
|
|
AU6342099A
(en)
|
1998-11-04 |
2000-05-22 |
Montell Technology Company B.V. |
Components and catalysts for the polymerization of olefins
|
|
US6329546B1
(en)
|
1999-01-12 |
2001-12-11 |
Laboratory Of Molecular Biophotonics |
Caged amino acids
|
|
US20030203900A1
(en)
|
1999-05-18 |
2003-10-30 |
Martin Quibell |
Cysteine protease inhibitors
|
|
RS50352B
(sr)
|
1999-06-10 |
2009-11-10 |
Warner-Lambert Company Llc., |
Monosupstituisane 3-propil gama-aminobuterne kiseline
|
|
DE60217322T2
(de)
|
2001-04-27 |
2007-10-04 |
Zenyaku Kogyo K.K. |
Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
PT1536827E
(pt)
|
2002-08-14 |
2009-03-20 |
Silence Therapeutics Ag |
Utilização de proteína cinase n beta
|
|
US6787664B2
(en)
|
2002-09-17 |
2004-09-07 |
Warner-Lambert Company Llc |
Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs
|
|
AU2002953255A0
(en)
|
2002-12-11 |
2003-01-02 |
Cytopia Research Pty Ltd |
Protein kinase inhibitors
|
|
AU2004228668B2
(en)
|
2003-04-03 |
2011-10-27 |
Park Funding, Llc |
PI-3 kinase inhibitor prodrugs
|
|
ES2382377T3
(es)
|
2003-05-30 |
2012-06-07 |
Gemin X Pharmaceuticals Canada Inc. |
Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
|
|
EP1692153A4
(en)
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
INHIBITION OF EXPRESSION OF SYK-KINASE
|
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
US20070212428A1
(en)
|
2004-06-04 |
2007-09-13 |
Mood Management Sciences, Inc. |
Methods and compositions for treating mood disorder
|
|
DE102004053407A1
(de)
|
2004-11-05 |
2006-05-11 |
Bayer Healthcare Ag |
Acylierte Nonadepsipeptide II
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
EP1853552A2
(en)
|
2005-02-18 |
2007-11-14 |
Innodia Inc. |
Diastereoisomers of 4-hydroxyisoleucine and uses thereof
|
|
PL1888550T3
(pl)
|
2005-05-12 |
2014-12-31 |
Abbvie Bahamas Ltd |
Promotory apoptozy
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
US7989622B2
(en)
|
2005-10-07 |
2011-08-02 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
|
JP5191391B2
(ja)
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
WO2007129161A2
(en)
|
2006-04-26 |
2007-11-15 |
F. Hoffmann-La Roche Ag |
Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
|
|
JP2010501566A
(ja)
|
2006-08-21 |
2010-01-21 |
プレクサ ファーマシューティカルズ， インコーポレイテッド |
中枢神経系障害の治療において使用するための多伝達物質トランスポータ阻害剤
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
EP2069339B1
(en)
|
2006-09-25 |
2011-05-18 |
Wockhardt Research Centre |
Substituted piperidinophenyl oxazolidinones
|
|
TWI397418B
(zh)
|
2006-10-10 |
2013-06-01 |
Otsuka Pharma Co Ltd |
抗憂鬱劑
|
|
CA2666310C
(en)
|
2006-10-20 |
2012-07-31 |
Merck & Co., Inc. |
Substituted imidazoles as bombesin receptor subtype-3 modulators
|
|
KR101566840B1
(ko)
|
2007-03-12 |
2015-11-06 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
TW200902019A
(en)
|
2007-04-26 |
2009-01-16 |
Ono Pharmaceutical Co |
Dicyclic heterocyclic compound
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US8431608B2
(en)
|
2007-08-17 |
2013-04-30 |
Icagen Inc. |
Heterocycles as potassium channel modulators
|
|
CN101903349B
(zh)
|
2007-08-27 |
2014-01-08 |
Abbvie德国有限责任两合公司 |
4-(4-吡啶基)-苯甲酰胺及其作为rock活性调节剂的应用
|
|
HUE029767T2
(en)
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
WO2010005726A2
(en)
|
2008-06-16 |
2010-01-14 |
Bind Biosciences Inc. |
Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
|
|
EP2350053B1
(en)
|
2008-10-17 |
2013-12-11 |
Whitehead Institute For Biomedical Research |
Modulators of MTOR Complexes
|
|
EP2443128B1
(en)
|
2009-06-19 |
2017-12-20 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters
|
|
WO2011012283A1
(en)
|
2009-07-30 |
2011-02-03 |
University Of Zurich |
Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
|
|
PH12012501535A1
(en)
|
2010-01-29 |
2012-10-22 |
Boehringer Ingelheim Int |
Substituted naphthyridines and their use as syk kinase inhibitors
|
|
ES2689103T3
(es)
|
2010-06-30 |
2018-11-08 |
Fujifilm Corporation |
Nuevo derivado de nicotinamida o sal del mismo
|
|
CN102464701B
(zh)
|
2010-11-08 |
2015-10-21 |
上海医药工业研究院 |
一类新型化合物、其制备方法及用途
|
|
WO2012076063A1
(en)
|
2010-12-10 |
2012-06-14 |
Rottapharm S.P.A. |
Pyridine amide derivatives as ep4 receptor antagonists
|
|
WO2012113847A1
(en)
|
2011-02-25 |
2012-08-30 |
Lonza Ltd |
Branched linker for protein drug conjugates
|
|
US9321727B2
(en)
|
2011-06-10 |
2016-04-26 |
Hoffmann-La Roche Inc. |
Pyridine derivatives as agonists of the CB2 receptor
|
|
EP2763975B1
(en)
|
2011-10-05 |
2016-04-06 |
Merck Sharp & Dohme Corp. |
3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
|
|
EP2589383A1
(en)
|
2011-11-06 |
2013-05-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
FKBP subtype-specific rapamycin analogue for use in treatment of diseases
|
|
WO2013142229A1
(en)
|
2012-03-19 |
2013-09-26 |
President And Fellows Of Harvard College |
Designing novel peptides for inducing fibronectin matrix assembly
|
|
EP2880014B1
(en)
*
|
2012-08-06 |
2017-05-17 |
Pitney Pharmaceuticals Pty Limited |
Compounds for the treatment of mtor pathway related diseases
|
|
WO2014127052A1
(en)
|
2013-02-13 |
2014-08-21 |
Zondlo Neal |
Perfluoro-tert-butyl hydroxyproline
|
|
WO2014145852A2
(en)
|
2013-03-15 |
2014-09-18 |
Knopp Biosciences Llc |
Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
|
|
US20160129030A1
(en)
|
2013-06-14 |
2016-05-12 |
The Brigham And Women's Hospital, Inc. |
Treatment of mtor hyperactive related diseases and disorders
|
|
EP3191116B1
(en)
|
2014-09-12 |
2020-11-25 |
The Whitehead Institute for Biomedical Research |
Methods of identifying modulators of sestrin-gator2 interaction and use of same to modulate mtorc1
|
|
AU2016342027B2
(en)
|
2015-10-23 |
2021-05-13 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
|
US20180327364A1
(en)
|
2015-11-13 |
2018-11-15 |
Brandeis University |
Mtor inhibitors and methods of use thereof
|
|
EP3445451B1
(en)
|
2016-04-21 |
2021-08-18 |
Baylor College of Medicine |
Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
|
|
PL3615019T3
(pl)
|
2017-04-26 |
2026-01-19 |
Navitor Pharmaceuticals, Inc. |
Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie
|
|
KR20250167147A
(ko)
*
|
2018-02-08 |
2025-11-28 |
오비드 테라퓨틱스 인크. |
이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도
|
|
EP3870158A4
(en)
*
|
2018-10-24 |
2022-08-10 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
|
US10926803B2
(en)
|
2019-07-17 |
2021-02-23 |
GM Global Technology Operations LLC |
Four rail front crush structure with load dissemination into eight element support structure
|
|
JP6689441B1
(ja)
|
2019-11-01 |
2020-04-28 |
エヌ・ティ・ティ・コミュニケーションズ株式会社 |
電子マネー管理システムおよび電子マネー管理方法
|
|
US11723890B2
(en)
|
2019-11-01 |
2023-08-15 |
Navitor Pharmaceuticals, Inc. |
Methods of treatment using an mTORC1 modulator
|